このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

乳児および幼児を対象とした治験用生弱毒化呼吸器合胞体ウイルスワクチンの同時投与研究 (CORAL)

2026年9月15日 更新者:Sanofi Pasteur, a Sanofi Company

健康な乳児および小児における治験中の弱毒化呼吸器合胞体ウイルス(RSV)ワクチンの抗体反応に対する定期小児ワクチンの併用投与の不干渉を評価するための第III相、無作為化、単盲検、プラセボ対照、多施設共同研究幼児用(コーラル)

This study is a Phase III, randomized, single-blind, placebo-controlled, multi-center study to be conducted in healthy infants and toddlers which will be enrolled at approximately 6 months of age (Cohort 1) and approximately 12 months of age (Cohort 2). The primary objective of the study will be to assess non-inferiority of the RSV infant and toddler (RSVt) vaccine antibody response when administered concomitantly with routine pediatric vaccines at 6 months of age (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine [Vaxelis® or Pentacel® and Recombivax HB®] Prevnar 20®, and RotaTeq®), and 12 months of age (M-M-R II, VARIVAX, and Prevnar 20 or per local country recommendations) compared to when administered non-concomitantly.

調査の概要

状態

終了しました

条件

介入・治療

詳細な説明

The study duration is approximately 9 months for each participant.

  • Cohort 1: Visits at 6, 7, and 8 and 9 months of age for both groups with visit at 10 months of age for Group 2 only
  • Cohort 2: Visits at 12, 13, 14 and 15 months of age for both groups with visit at 16 months of age for Group 4 only
  • Routine pediatric vaccines (authorized auxiliary medicinal products (AxMP) will be administered at 6 months in Cohort 1 and 12 months of age in Cohort 2, as per Advisory Committee on Immunization Practice (ACIP) or local country recommendations.

研究の種類

介入

入学 (実際)

2226

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35205
        • Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400007
      • Grand Bay、Alabama、アメリカ、36541
        • South Alabama Medical Clinic- Site Number : 8400065
      • Mobile、Alabama、アメリカ、36608
        • MedPharmics - Mobile - Dauphin Street- Site Number : 8400017
    • Arkansas
      • Fayetteville、Arkansas、アメリカ、72703
        • Northwest Arkansas Pediatric Clinic- Site Number : 8400002
    • California
      • Bell Gardens、California、アメリカ、90201
        • Alliance Research Institute - Bell Gardens - Garfield Avenue- Site Number : 8400040
      • Huntington Park、California、アメリカ、90255
        • Matrix Clinical Research - Huntington Park- Site Number : 8400018
      • La Mesa、California、アメリカ、91942
        • Paradigm Clinical Research Centers- Site Number : 8400059
      • Los Angeles、California、アメリカ、90057
        • Matrix Clinical Research - Los Angeles- Site Number : 8400008
      • Oakland、California、アメリカ、94611
        • Kaiser Permanente - Oakland Medical Center- Site Number : 8400047
      • Palo Alto、California、アメリカ、94304
        • Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400070
      • Roseville、California、アメリカ、95661
        • Kaiser Permanente - Sierra Gardens- Site Number : 8400063
      • Sacramento、California、アメリカ、95815
        • Kaiser Permanente - Point West Medical Offices- Site Number : 8400064
      • San Jose、California、アメリカ、95119
        • Kaiser Permanente - San Jose Medical Center- Site Number : 8400060
      • Santa Clara、California、アメリカ、95051
        • Kaiser Permanente - Santa Clara Medical Center- Site Number : 8400061
      • Sherman Oaks、California、アメリカ、91356-4173
        • Integrated Clinical Research LLC- Site Number : 8400036
      • Walnut Creek、California、アメリカ、94596
        • Kaiser Permanente - Walnut Creek Medical Center- Site Number : 8400062
    • District of Columbia
      • Washington D.C.、District of Columbia、アメリカ、20016
        • Velocity Clinical Research - Washington DC- Site Number : 8400050
    • Florida
      • Doral、Florida、アメリカ、33166
        • Prohealth Research Center- Site Number : 8400068
      • Hollywood、Florida、アメリカ、33021
        • The Medici Medical Research- Site Number : 8400055
      • Miami、Florida、アメリカ、33126
        • Dade Research Center- Site Number : 8400014
      • Miami Lakes、Florida、アメリカ、33014
        • Riveldi Biomedical Research and Associates - Miami Lakes- Site Number : 8400015
      • Pensacola、Florida、アメリカ、32501
        • SEC Clinical Research - Pensacola- Site Number : 8400034
      • Tampa、Florida、アメリカ、33613
        • PAS Research- Site Number : 8400005
    • Idaho
      • Idaho Falls、Idaho、アメリカ、83404
        • Leavitt Women's Healthcare- Site Number : 8400009
    • Iowa
      • Sioux City、Iowa、アメリカ、51106
        • Velocity Clinical Research - Sioux City- Site Number : 8400054
    • Kansas
      • El Dorado、Kansas、アメリカ、67042
        • Alliance for Multispeciality Research - El Dorado- Site Number : 8400019
    • Kentucky
      • Lexington、Kentucky、アメリカ、40536
        • University of Kentucky Chandler Medical Center- Site Number : 8400051
    • Louisiana
      • New Orleans、Louisiana、アメリカ、70119
        • Velocity Clinical Research - New Orleans- Site Number : 8400058
      • New Orleans、Louisiana、アメリカ、70125
        • Research Works INC- Site Number : 8400044
    • Mississippi
      • Gulfport、Mississippi、アメリカ、39503
        • Velocity Clinical Research - Gulfport- Site Number : 8400011
    • Missouri
      • Springfield、Missouri、アメリカ、65802
        • QPS Bio-Kinetic Clinical Applications- Site Number : 8400046
    • Montana
      • Great Falls、Montana、アメリカ、59405
        • Boeson Research - Great Falls- Site Number : 8400041
      • Missoula、Montana、アメリカ、59804
        • Boeson Research - Missoula- Site Number : 8400006
    • Nebraska
      • Grand Island、Nebraska、アメリカ、68803
        • Velocity Clinical Research - Grand Island- Site Number : 8400016
      • Lincoln、Nebraska、アメリカ、68516
        • Midwest Childrens Health Research Institute- Site Number : 8400038
      • Omaha、Nebraska、アメリカ、68134
        • Velocity Clinical Research - Omaha- Site Number : 8400001
    • Nevada
      • Henderson、Nevada、アメリカ、89014
        • PAS Research - Henderson- Site Number : 8400049
    • New York
      • Garden City、New York、アメリカ、11530
        • NYU Langone Cardiothoracic Surgery Associates - Garden City- Site Number : 8400048
      • Liverpool、New York、アメリカ、13088
        • Summerwood Pediatrics- Site Number : 8400021
      • Syracuse、New York、アメリカ、13210
        • SUNY Upstate Medical University - Syracuse- Site Number : 8400029
    • Ohio
      • Dayton、Ohio、アメリカ、45414
        • Ohio Pediatrics - Dayton- Site Number : 8400033
      • Dayton、Ohio、アメリカ、45409
        • Dayton Clinical Research- Site Number : 8400030
      • South Euclid、Ohio、アメリカ、44121
        • Senders Pediatrics- Site Number : 8400022
    • Oregon
      • Gresham、Oregon、アメリカ、97030
        • Cyn3rgy Research- Site Number : 8400053
    • Pennsylvania
      • Erie、Pennsylvania、アメリカ、16506
        • Square-1 Clinical Research- Site Number : 8400031
      • Pittsburgh、Pennsylvania、アメリカ、15227
        • Pas Research - Pittsburgh- Site Number : 8400043
    • South Carolina
      • Charleston、South Carolina、アメリカ、29407
        • Neighbors Pediatrics- Site Number : 8400072
      • Greenville、South Carolina、アメリカ、29607
        • Tribe Clinical Research - Greenville - Verdae Boulevard- Site Number : 8400012
    • Texas
      • Corpus Christi、Texas、アメリカ、78413
        • South Texas Clinical Research- Site Number : 8400004
      • Dallas、Texas、アメリカ、75230
        • Javara - Privia Medical Group North Texas - Dallas- Site Number : 8400003
      • Edinburg、Texas、アメリカ、78539
        • PAS Research - Children's Care Clinic- Site Number : 8400035
      • Fort Worth、Texas、アメリカ、76104
        • Helios Clinical Research - Fort Worth - 8th Avenue- Site Number : 8400020
      • Houston、Texas、アメリカ、77008
        • Ventavia Research Group - Houston - North Loop West- Site Number : 8400010
      • Houston、Texas、アメリカ、77065
        • DM Clinical Research - Houston - Jones Road- Site Number : 8400052
      • Houston、Texas、アメリカ、77070
        • Mercury Clinical Research - Houston - Savoy Drive- Site Number : 8400045
      • Houston、Texas、アメリカ、77090
        • Houston Clinical Research Associates- Site Number : 8400013
      • Houston、Texas、アメリカ、77030
        • The University of Texas Health Science Center- Site Number : 8400037
      • Houston、Texas、アメリカ、77071
        • La Providence Pediatrics & Family Clinics- Site Number : 8400039
      • League City、Texas、アメリカ、77555
        • University of Texas Medical Branch at Galveston- Site Number : 8400057
      • League City、Texas、アメリカ、77573
        • Maximos Ob/Gyn- Site Number : 8400024
      • Plano、Texas、アメリカ、75093
        • Research Your Health- Site Number : 8400066
      • Richmond、Texas、アメリカ、77469
        • Pediatric Center - Richmond- Site Number : 8400032
      • Tomball、Texas、アメリカ、77375
        • North Houston Internal Medicine & Pediatric Clinic- Site Number : 8400025
    • Utah
      • Orem、Utah、アメリカ、84057
        • Utah Valley Pediatrics - Orem- Site Number : 8400067
      • Pleasant View、Utah、アメリカ、84404
        • Ogden Clinic - Mountain View - CCT Research- Site Number : 8400056
      • Roy、Utah、アメリカ、84067
        • Wee Care Pediatrics - Roy- Site Number : 8400071
      • Caguas、プエルトリコ、00725
        • Investigational Site Number : 6300001
      • Ponce、プエルトリコ、00716
        • Investigational Site Number : 6300003
      • Trujillo Alto、プエルトリコ、00976
        • Investigational Site Number : 6300004
      • Mexico City、メキシコ、06760
        • Investigational Site Number : 4840004
    • Mexico City
      • Mexico City、Mexico City、メキシコ、04530
        • Investigational Site Number : 4840001
    • Morelos
      • Temixco、Morelos、メキシコ、62587
        • Investigational Site Number : 4840002

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

6ヶ月~1年 (子)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Aged 6 months for Cohort 1 and 12 months for Cohort 2 on the day of inclusion ("6 months" means from the day of the 6-month birthday to the day before the 7-month birthday and "12 months" means from the day of the 12-month birthday to the day before the 13-month birthday)
  • Participants who are healthy as determined by medical evaluation including medical history and physical examination
  • For Cohort 1: Infant received doses of vaccines containing hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae type B (Hib), and inactivated poliovirus vaccine (IPV) antigens, with Advisory Committee on Immunization Practice (ACIP) recommended vaccines. The last dose(s) of these vaccines must be at least 28 days before the first study visit
  • Infant received the recommended doses of a recommended pneumococcal conjugate vaccine (as per local schedule) at least 28 days before the first study visit.

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known previous infection with diphtheria, tetanus, Hib, measles, mumps, rubella, rotavirus, pneumococcus, polio, hepatitis B virus
  • Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • History of medically diagnosed wheezing
  • Any acute febrile illness in the past 48 hours that according to investigator judgment is significant enough to interfere with successful inoculation on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Probable or confirmed ongoing case of viral respiratory infection (including COVID 19, influenza, rhinovirus, etc.) at the time of enrollment. A prospective participant should not be included in the study until the respiratory infection has resolved.
  • Member of a household that contains an immunocompromised individual, including, but not limited to:
  • A person living with human immunodeficiency virus (HIV)
  • A person who has received chemotherapy within the 12 months prior to study enrollment
  • A person who has received (within the past 6 months) or is receiving (at the time of enrollment) immunosuppressant agents
  • A person living with a solid organ or bone marrow transplant
  • Potential close contact with other immunocompromised individual within 30 days after each vaccination as per investigator's discretion
  • History of definitive contraindications to any of the concomitant vaccines that will be administered as part of the study protocol
  • Participant's biological mother with previous receipt or planned administration of an investigational RSV vaccine during pregnancy and/or breastfeeding
  • Receipt of any vaccine in the 4 weeks preceding RSVt vaccine administration or planned receipt of any vaccine outside of study protocol in the 4 weeks following RSVt vaccine administration, except for influenza and/or COVID-19 vaccination, which may be received at least 1 week before or 1 week after RSVt vaccine administration
  • Previous receipt of an investigational RSV vaccine or receiving any anti RSV product (such as ribavirin or RSV immune globulin) at the time of enrollment
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Receipt of intranasal and intra-ocular medications within 3 days prior to study enrollment
  • Previous receipt of an RSV monoclonal antibody within 6 months prior to the first study vaccine administration or planned receipt for duration of the study
  • For Cohort 1: Prior receipt of routine 6-month pediatric vaccine doses (as per local schedule)
  • For Cohort 2: Prior receipt of routine 12-month pediatric vaccine doses (as per local schedule)
  • Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure

Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)

Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

他の名前:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

他の名前:
  • バクセリス®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

他の名前:
  • ペンタセル®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

他の名前:
  • RECOMBIVAX HB® または代替一価 B 型肝炎ワクチン

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

他の名前:
  • プレブナー 20®

Pharmaceutical form:Oral solution-Route of administration:Oral

他の名前:
  • ロタテック®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

実験的:Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)

Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

他の名前:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

他の名前:
  • バクセリス®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

他の名前:
  • ペンタセル®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

他の名前:
  • RECOMBIVAX HB® または代替一価 B 型肝炎ワクチン

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

他の名前:
  • プレブナー 20®

Pharmaceutical form:Oral solution-Route of administration:Oral

他の名前:
  • ロタテック®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

実験的:Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months)

Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 12 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered non-concomitantly at 13 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

他の名前:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

他の名前:
  • プレブナー 20®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular

他の名前:
  • M-M-R® II

Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular

他の名前:
  • VARIVAX®
実験的:Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months)

Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 13 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered concomitantly at 12 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

他の名前:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

他の名前:
  • プレブナー 20®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular

他の名前:
  • M-M-R® II

Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular

他の名前:
  • VARIVAX®

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
RSV A serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3
時間枠:Day 85

Antibody titers at Day 85

Day 85
RSV B serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3
時間枠:Day 85

Antibody titers at Day 85

Day 85
RSV A serum neutralizing antibody titers at Day 113 Groups 2 and 4
時間枠:Day 113

Antibody titers at Day 113

Day 113
RSV B serum neutralizing antibody titers at Day 113 Groups 2 and 4
時間枠:Day 113

Antibody titers at Day 113

Day 113

二次結果の測定

結果測定
メジャーの説明
時間枠
Anti- hepatitis B surface antigen (HBsAg) Immunoglobulin g (IgG) antibody (A)b concentrations ≥ 10 milli international units per milliliter (mIU/mL) Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti- polyribosylribitol phosphate (PRP) Ab concentrations ≥ 0.15 micrograms per milliliter (µg/mL) Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-poliovirus types (1, 2, and 3) Ab titers ≥ 1:8 Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-pertussis Ab concentrations pertussis toxin, filamentous hemagglutinin , pertactin, fimbriae (PT, FHA, PRN, FIM) Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-diphtheria Ab concentrations ≥ 0.1 IU/mL Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-tetanus Ab concentrations ≥ 0.1 IU/mL Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-pneumococcal Ab concentrations measured by electrochemiluminescence (ECL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-measles Ab concentrations ≥ 255 mIU/mL Cohort 2
時間枠:28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-mumps Ab concentrations ≥ 10 antibody units (AbU/mL) Cohort 2
時間枠:28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-rubella Ab concentrations ≥ 10 IU/mL Cohort 2
時間枠:28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-varicella Ab concentrations ≥ 5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) units/mL Cohort 2
時間枠:28 days after the 12 month routine vaccinations

Antibody 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-pneumococcal Ab concentrations measured by ECL Cohort 2
時間枠:28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-PRP Ab concentrations (µg/mL) Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-diphtheria Ab concentrations (IU/mL) Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-diphtheria Ab concentrations ≥ 0.01 IU/mL Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-tetanus Ab concentrations (IU/mL) Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-tetanus Ab concentrations ≥ 0.01 IU/mL Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-HBsAg Ab concentrations (mIU/mL) Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-HBsAg Ab concentrations ≥ 100 mIU/mL Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-poliovirus types (1, 2, and 3) Ab titers Cohort 1
時間枠:28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-measles Ab concentrations (mIU/mL) Cohort 2
時間枠:28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-mumps Ab concentrations (AbU/mL) Cohort 2
時間枠:28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-rubella Ab concentrations (IU/mL) Cohort 2
時間枠:28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-varicella Ab concentrations (gpELISA units/mL)
時間枠:28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
RSV A serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2
時間枠:Day 1

Antibody titers at Day 1

Day 1
RSV B serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2
時間枠:Day 1

Antibody titers at Day 1

Day 1
RSV A serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 1 Cohort 1 and Cohort 2
時間枠:28 days post-dose 2

Antibody titers 28 days post-dose 2

28 days post-dose 2
RSV B serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 Cohort 1 and Cohort 2
時間枠:28 days post-dose 2

Antibody titers 28 days post-dose 2

28 days post-dose 2
Presence of solicited administration site reactions within 21 days after each investigational medicinal product (IMP) administration Cohort 1 and Cohort 2
時間枠:21 days after each IMP administration

Number of participants experiencing solicited administration site reactions

21 days after each IMP administration
Presence of solicited systemic reactions within 21 days after each IMP administration Cohort 1 and Cohort 2
時間枠:21 days after each IMP administration

Number of participants experiencing solicited systemic site reactions

21 days after each IMP administration
Presence of unsolicited systemic adverse events (AEs) reported in the 30 minutes after each study intervention administration Cohort 1 and Cohort 2
時間枠:Within 30 minutes after each study intervention administration

Number of participants experiencing unsolicited systemic adverse events

Within 30 minutes after each study intervention administration
Presence of unsolicited AEs within 28 days after each study intervention administration Cohort 1 and Cohort 2
時間枠:Within 28 days after each study intervention administration

Number of participants experiencing unsolicited AEs

Within 28 days after each study intervention administration
Presence of medically attended adverse events (MAAEs) throughout the study Cohort 1 and Cohort 2
時間枠:Throughout the study, approximately 9 months

Number of participants experiencing MAAEs

Throughout the study, approximately 9 months
Presence of serious adverse events (SAEs) throughout the study Cohort 1 and Cohort 2
時間枠:Throughout the study, approximately 9 months

Number of participants experiencing SAEs

Throughout the study, approximately 9 months
Presence of adverse events of special interest (AESIs) throughout the study Cohort 1 and Cohort 2
時間枠:Throughout the study, approximately 9 months

Number of participants experiencing AESIs

Throughout the study, approximately 9 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年5月13日

一次修了 (実際)

2025年9月18日

研究の完了 (実際)

2025年9月18日

試験登録日

最初に提出

2024年4月29日

QC基準を満たした最初の提出物

2024年4月29日

最初の投稿 (実際)

2024年5月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年9月15日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • VAD00016
  • VAD00016 (その他の識別子:Sanofi Identifier)
  • U1111-1290-7356 (レジストリ識別子:ICTRP)
  • 2024-000262-15 (EudraCT番号)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。